Charles “Charlie” Fuchs is joining Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit as SVP and global head of product development for oncology and hematology. Fuchs, who will start March 1 and be based in South San Francisco, is...

If the U.S. hopes to generate substantial, meaningful data on therapies for COVID-19 and future pandemics, it will need to overhaul the clinical trial ecosystem to prioritize master protocols.  At...

CDC said the second dose of COVID-19 vaccines from Moderna Inc. (NASDAQ:MRNA) and partners BioNTech SE (NASDAQ:BNTX) and Pfizer Inc. (NYSE:PFE) can be administered up to six weeks after the first dose. The prior recommendation had been three...

An efficacy readout in a small Phase IIa trial of Aclaris’ oral therapy for rheumatoid arthritis has more than tripled the company’s market cap, representing its first major value-creating event since it restructured in 2H19...

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...

Gracell has followed fellow CAR T companies Legend, Allogene and bluebird onto NASDAQ with an oversubscribed IPO that the Suzhou company hopes will help put it on the map as a global player in the space....

Pacific Biosciences of California Inc. (NASDAQ:PACB) filled two newly created posts via the hiring of a pair of Illumina Inc. (NASDAQ:ILMN) veterans: Mark Van Oene as COO and Peter Fromen as chief commercial officer. Van Oene...

A $236 million crossover round could set up Affinivax for a public listing as the biotech looks to take more vaccines into the clinic beyond its partnered pneumococcal program. Rock Springs Capital and Foresite Capital...

With crossover investors lining up to participate, biotechs Immuneering, Terns and Ikena each raised rounds that could augur upcoming public offerings. The deals come as a host of biotechs will likely...

The New Year kicks off with the new — a new U.S. president readying to enter the White House with a new take on drug pricing, and investors eyeing new modalities — and too much of the...